Rafael Pharmaceuticals to Present New Data Validating Efficacy of CPI-613 in Treating Acute Myeloid Leukemia at the 2017 American Society of Hematology Annual Meeting & Exposition

Newark, New Jersey, UNITED STATES

Newark, NJ, Dec. 07, 2017 (GLOBE NEWSWIRE) -- CPI-613 is Rafael Pharmaceuticals' lead drug candidate, a first-in-class anticancer compound designed to disrupt the altered energy production pathways in cancer cells by targeting mitochondrial metabolism. It selectively targets the tricarboxylic acid (TCA) cycle, a process essential to tumor cell proliferation and survival. The new data from the below-listed presentation was collected from a single arm phase II study aimed at further validating the clinical efficacy of CPI-613 in treating acute myeloid leukemia (AML).

PRESENTATION TITLE: Interim Analysis of a Single Arm Phase II Study of CPI-613 in Combination with High Dose Cytarabine and Mitoxantrone for Patients with Relapsed or Refractory AML

  • Date/Time: Sunday, December 10, 2017 6:00-8:00 PM PT
  • Session: 616. Acute Myeloid Leukemia: Novel Therapy, excluding Transplantation: Poster II 
  • Location: Georgia World Congress Center, Bldg A, Lvl 1, Hall A2
  • Publication #: 2626 
  • Scheduled Presenter: Timothy S. Pardee, M.D. Ph.D., Section on Hematology and Oncology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, NC     

INTERVIEW: Dr. Pardee, Rafael Pharmaceutical’s CMO and presenter of the study, will be available for media interviews upon request.

CONTACT: Sanjeev Luther, Sanjeev.luther@rafaelpharma.com, for more information.

About Rafael Pharmaceuticals, Inc.

Rafael Pharmaceuticals, Inc. is a clinical-stage, oncology-focused pharmaceutical company committed to the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Rafael’s primary objective is to develop highly selective and effective agents with minimal toxic effects on normal cells and tissues. Rafael’s first-in-class clinical lead compound, CPI-613 is being evaluated in multiple Phase I, I/II, and II clinical studies. The U.S. Food and Drug Administration (FDA) has given Rafael approval to initiate pivotal clinical trials in pancreatic cancer and acute myeloid leukemia (AML), and has designated CPI-613 an orphan drug for the treatment of pancreatic cancer, AML, and myelodysplastic syndromes (MDS). The company's investors include IDT Corporation (NYSE: IDT). For more information, visit http://www.rafaelpharma.com/.

Safe Harbor Statement

This press release contains forward-looking statements. These statements relate to future events or the company’s future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may", "will", "should", "expect", "plan", "anticipate", "believe", "estimate", "predict", "potential" or "continue", the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.